• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

New Report Gives Forecasts to 2011 for the Medicated Skin Care Market in Sweden

Posted on: Friday, 21 December 2007, 09:00 CST

Research and Markets (http://www.researchandmarkets.com/reports/c77928) has announced the addition of Euromonitor International's new report: Medicated Skin Care in Sweden to their offering.

Our Medicated Skin Care in Sweden report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data (2001-2006), allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market - be they new product developments, distribution or pricing issues. Forecasts to 2011 illustrate how the market is set to change.

Product coverage: acne treatments, antipruritics, topical germicidals/antiseptics, topical allergy remedies/antihistamines, topical antifungals, vaginal antifungals, antiparasitics/lice (head and body) treatments, medicated shampoos, hair loss treatments, lip care treatments, haemorrhoid treatments, child-specific medicated skin care, nappy (diaper) rash treatments

Data coverage: market sizes (historic and forecasts), company shares and brand shares

Why buy this report?

Get a detailed picture of the medicated skin care industry

Identify factors driving change

Understand the competitive environment, the market's major players and leading brands

Use five-year forecasts to assess how the market is predicted to develop

With a network of over 600 analysts worldwide, we have the unique capability to develop reliable information resources to help drive informed strategic planning.

Executive summary

Strong growth seen again in OTC in 2006

The OTC healthcare industry continued to show a healthy development in 2006. Increasing disposable incomes and a continuously growing health awareness certainly impacted positively on growth, but it was particularly heavy advertising of OTC products that had the greatest impact. Due to the increasing share of generics in 2005, manufacturers of branded products drastically increased their marketing budgets, which naturally spurred growth. A number of switches from Rx to OTC further contributed to growth, where the launch of a number of diclofenac brands, for example, Voltaren from Novartis, were important.

Product areas with particularly strong growth in 2006

A number of product areas were more successful than others in 2006, due to both increasing demand as well as manufacturer activities. In analgesics, topical analgesics continued to grow rapidly, thanks to being previously underdeveloped as well as due to heavy advertising. Allergy remedies across all sectors also saw strong growth thanks to a very intense, if short, pollen period during the spring of 2006. Growth was also strong in medicated skin care, where antifungals and lip care treatments in particular saw strong growth thanks to increasing advertising. The large vitamins and dietary supplements sector was among the poorest performing product areas, mainly because many consumers abandoned dietary supplements as they were increasingly regarded as inefficient.

A handful of companies continue to dominate sales

The Swedish OTC market was led by a handful of multinationals, of which Pfizer, AstraZeneca and Procter & Gamble were the most successful. While the latter reached its position thanks to dominating the large medicated confectionery sector, the other two players were previous standalone companies, Pharmacia and Astra, which had traditionally had very strong connections to the state-owned monopoly pharmacy and had become the sole suppliers of products in many categories.

Deregulation of OTC retail market coming soon

Following the right wing coalition's victory in the elections of September 2006, a deregulation of the pharmacy retail monopoly in Sweden is expected to take place as early as 2008, and even earlier for certain product areas, such as NRT smoking cessation aids. The coalition had previously announced its intention to deregulate the monopoly OTC market. According to most industry observers, a deregulation will spur sales as availability increases.

Companies mentioned: Recip AB Meda AB Antula Healthcare AB Abigo Medical AB Midelfart Sonesson AB

For more information visit http://www.researchandmarkets.com/reports/c77928

Source: Business Wire

More News in this Category